Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B – Genetic Engineering & Biotechnology News

Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B  Genetic Engineering & Biotechnology NewsAkcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)  GlobeNewswireAfter leadership shuffle, Akcea hands heart drug to Pfizer for $250M  FierceBiotechAkcea out-licenses antisense candidate to Pfizer for up to $1.5B  Seeking AlphaAkcea Therapeutics Shares Up 44% on Pfizer Licensing Agreement  Morningstar.comView full coverage on Google News

Read More